We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $11.7B
1-Year Est. Return 174.13%
This Fund
S&P 500
This Quarter Est. Return
+13.47%
1 Year Est. Return
+174.13%
3 Year Est. Return
+466.81%
5 Year Est. Return
+622.69%
10 Year Est. Return
+19,772.83%
AUM
$10B
AUM Growth
+$66.4M
Cap. Flow
+$419M
Cap. Flow %
4.17%
Top 10 Hldgs %
49.99%
Holding
98
New
7
Increased
30
Reduced
13
Closed
10

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$282M
2
CELC icon
Celcuity
CELC
+$271M
3
ERAS icon
Erasca
ERAS
+$189M
4
TNGX icon
Tango Therapeutics
TNGX
+$164M
5
IRTC icon
iRhythm Holdings
IRTC
+$70.2M

Top Sells

Rank Stock Value
1
PEN icon
Penumbra
PEN
+$269M
2
AXSM icon
Axsome Therapeutics
AXSM
+$162M
3
PODD icon
Insulet
PODD
+$92.3M
4
MASI
Masimo
MASI
+$88.9M
5
APLS
Apellis Pharmaceuticals
APLS
+$85.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.92%
2 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATAI icon
76
AtaiBeckley Inc
ATAI
$2.69B
$7.08M 0.07%
2,000,000
– –
CBIO
77
Crescent Biopharma
CBIO
$637M
$6.85M 0.07%
372,856
– –
LRMR icon
78
Larimar Therapeutics
LRMR
$453M
$6.75M 0.07%
1,500,000
-1,625,000
-52% -$6.5M
TENX icon
79
Tenax Therapeutics
TENX
$67.4M
$5.92M 0.06%
370,246
-8,100
-2% -$110K
DFTX
80
Definium Therapeutics
DFTX
$5.73B
$5.67M 0.06%
300,000
– –
LMRI
81
Lumexa Imaging Holdings
LMRI
$1.15B
$5.59M 0.06%
650,000
– –
FDMT icon
82
4D Molecular Therapeutics
FDMT
$637M
$4.43M 0.04%
475,737
– –
MDLN
83
Medline Inc
MDLN
$31.4B
$3.12M 0.03%
70,000
– –
OMDA
84
Omada Health Inc
OMDA
$1.46B
$2.51M 0.03%
200,000
– –
IRON icon
85
Disc Medicine
IRON
$3.03B
$1.92M 0.02%
30,000
– –
IMA
86
ImageneBio Inc
IMA
$66.3M
$1.67M 0.02%
334,445
– –
XGN icon
87
Exagen
XGN
$161M
$1.19M 0.01%
395,231
-395,231
-50% -$1.53M
RCKTW icon
88
Rocket Pharmaceuticals Warrant
RCKTW
$117K
$7.21K ﹤0.01%
350,000
– –
ALUR
89
DELISTED
Allurion Technologies
ALUR
– –
-5,891,430
Closed -$7.25M
AXSM icon
90
Axsome Therapeutics
AXSM
$11.2B
– –
-888,001
Closed -$162M
CRVS icon
91
Corvus Pharmaceuticals
CRVS
$1.25B
– –
-447,607
Closed -$3.45M
GPCR icon
92
Structure Therapeutics
GPCR
$3.87B
– –
-100,000
Closed -$6.96M
IQV icon
93
IQVIA
IQV
$39B
– –
-46,000
Closed -$10.4M
MASI
94
DELISTED
Masimo
MASI
– –
-683,294
Closed -$88.9M
PEN icon
95
Penumbra
PEN
$12.9B
– –
-866,499
Closed -$269M
PODD icon
96
Insulet
PODD
$9.94B
– –
-324,600
Closed -$92.3M
RAPT
97
DELISTED
RAPT Therapeutics
RAPT
– –
-1,637,165
Closed -$55.5M
TEM
98
Tempus AI
TEM
$9.4B
– –
-200,000
Closed -$11.8M
1 2 3
4

Similar funds

CIM
Centersquare Investment Management Conshohocken, Pennsylvania $11.7B AUM 20.39% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
UE
Unisphere Establishment Vaduz, Liechtenstein $11.7B AUM 0.31% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $11.8B AUM 25.68% 1-Year Est. Return
CCMT
CMT Capital Markets Trading Frankfurt, Germany $11.8B AUM 39.43% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

RTW Investments's Q1 2026 Portfolio in Review

As of Q1 2026, RTW Investments held 98 positions worth $10B, up 0.67% from $9.98B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

RTW Investments deployed $419M of net new capital in Q1 2026, opening 7 new positions and adding to 30 existing holdings. Its largest new stake was Waystar Holding Corp: 1,630,000 shares worth $39.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Apellis Pharmaceuticals, an estimated $85.8M trimmed.

  • RTW Investments's largest Q1 2026 buy was Waystar Holding Corp: 1,630,000 shares worth $39.3M.
  • RTW Investments added most to CG Oncology in Q1 2026, an estimated $282M increase.
  • RTW Investments's biggest Q1 2026 reduction was Apellis Pharmaceuticals, cutting an estimated $85.8M.
  • RTW Investments fully exited Penumbra in Q1 2026, selling an estimated $269M.
  • RTW Investments's ten largest holdings make up 50% of its $10B portfolio in Q1 2026.
  • RTW Investments opened 7 new positions and closed 10 in Q1 2026.
  • RTW Investments's portfolio value rose 0.67% quarter-over-quarter to $10B.

Based on RTW Investments's 13F filing for Q1 2026, filed 15 May 2026.